1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Bristol-Myers Squibb Company

Bristol-Myers Squibb Company

BRM.DE
Bristol-Myers Squibb CompanyDE flagDeutsche Börse
50.41
EUR
-0.30
- -
102.94BMarket Cap
Bristol-Myers Squibb Company
BRM.DE
(Deutsche Börse)

Recent

price

50.41

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
11.37
12.5
10.55
9.97
9.58
9.93
11.63
12.63
13.82
15.33
18.83
21.54
21.67
21.75
23.83
23.69
23.81
Revenue per Share
1.81
2.18
1.17
1.56
1.21
0.94
2.67
0.61
3.01
2.02
-3.99
3.25
2.97
3.88
-4.41
3.47
3.57
Basic EPS, GAAP
2.37
2.63
3.83
1.83
1.58
1.26
1.83
3.21
4.33
4.82
6.22
7.53
6.13
6.7
7.49
6.96
6.53
Free Cash Flow per Basic Share
1.29
1.33
1.37
1.4
1.45
1.49
1.52
1.57
1.6
1.57
1.8
2.04
2.18
2.29
2.4
2.48
2.49
Dividend per Share
18.6
19.58
19.73
20.18
19.77
19.1
20.19
19.08
21
20.39
9.55
11.2
12.11
14.04
7.5
8.45
9.12
Book Value per Share
4.11
4.21
-1.66
3.54
3.74
3.67
4.84
2.29
3.98
-20.39
-15.99
-12.67
-12.39
-9.26
-14.29
-11.11
-9.89
Tangible Book Value per Share
1,713
1,700
1,670
1,644
1,657
1,667
1,671
1,645
1,633
1,705
2,258
2,153
2,130
2,069
2,027
2,034
2,036
Basic Weighted Avg Shares
19,484
21,244
17,621
16,385
15,879
16,560
19,427
20,776
22,561
26,145
42,518
46,385
46,159
45,006
48,300
48,195
48,483
Sales/Revenue/Turnover
30.54
31.24
22.31
17.89
10.79
10.45
23.36
16.59
22.79
16.5
5.15
18.4
19.72
18.21
12.19
28.48
28.03
Operating Margin (%)
607
628
681
763
467
376
382
789
637
1,746
10,380
10,686
10,276
9,760
9,600
4,011
3,593
Depreciation Expense
3,102
3,709
1,960
2,563
2,004
1,565
4,457
1,007
4,920
3,439
-9,015
6,994
6,327
8,025
-8,948
7,054
7,275
Net Income, GAAP
25.66
24.65
- -
10.76
14.78
21.47
23.8
81
17.11
30.45
- -
13.39
17.74
4.74
- -
24.36
24.22
Effective Tax Rate (%)
15.92
17.46
11.12
15.64
12.62
9.45
22.94
4.85
21.81
13.15
-21.2
15.08
13.71
17.83
-18.53
14.64
15.01
Profit Margin (%)
6,534
7,538
1,242
6,476
6,147
2,398
4,863
5,291
7,062
11,050
11,112
11,394
5,383
9,508
6,006
5,973
8,050
Working Capital
5,328
5,376
6,568
7,981
7,242
6,550
5,716
6,975
5,646
44,059
49,169
40,479
36,317
38,183
48,973
44,676
43,922
LT Debt
15,638
15,867
13,638
15,236
14,983
14,424
16,347
11,847
14,127
51,698
37,882
36,006
31,118
29,485
16,388
18,506
20,102
Total Equity
20.83
23.52
- -
11.69
6.26
6.1
15.51
3.06
20.59
4.92
- -
8.64
9.75
10.86
- -
15.61
15.17
Return on Invested Capital (%)
4.83
5.97
- -
6.65
5.23
4.14
11.44
2.69
12.43
6.24
- -
11.36
10.74
13.3
- -
12.97
13.03
Return on Capital (%)
9.87
11.39
5.92
7.75
6.08
4.85
13.6
3.09
14.98
9.96
-32
30.62
25.36
29.26
-40.43
43.55
41.6
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
4,723
2,463
2,506
LT Borrowings
44,469
42,850
42,152
LT Finance Leases
1,849
1,826
1,770
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2,036
2,036
2,042
Market Capitalization
91,493
109,919
123,042

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
35,630
29,390
27,208
Cash, Cash Equivalents & STI
16,502
10,673
10,486
Accounts Receivable, Net
9,624
9,592
7,947
Inventories
2,758
2,690
2,756
Total Current Liabilities
28,136
23,417
19,158
Payables & Accruals
7,084
6,321
6,936
ST Debt
4,723
2,463
2,506
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
18.9%
-11.06%
12.92%
Free Cash Flow
24.39%
0.97%
-6.81%
Net Income, GAAP
-44.69%
-110.12%
-178.83%
Sales/Revenue/Turnover
12.46%
2.64%
-0.22%
Total Cash Common Dividend
8.2%
4.38%
3.74%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
11,865
12,201
11,892
12,342
48,300
2025
11,201
12,269
12,222
12,503
48,195
2026
11,489
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-5.89
0.83
0.6
0.04
-4.41
2025
1.21
0.64
- -
0.53
3.47
2026
1.31
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.6
0.6
0.6
0.6
2.4
2025
0.62
0.62
- -
0.62
2.48
2026
0.63
- -
- -
- -
- -
Similar Companies
Novartis AG (NVS)
TTK Healthcare Limited (TTKHLTCARE.NS)
Perseus Proteomics Inc. (4882.T)
Genovate Biotechnology Co., Ltd. (4130.TWO)
Novo Nordisk A/S (NOVC.DE)
SMS Pharmaceuticals Limited (SMSPHARMA.NS)
Business
Bristol-Myers Squibb Company is a global biopharmaceutical corporation engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of pharmaceutical products worldwide. The company’s core products and services include biopharmaceutical therapies targeting oncology, immunology, cardiovascular disease, and fibrosis. Key product categories include specialty pharmaceuticals such as cancer immunotherapies; oral targeted therapies; immunology drugs including treatments for autoimmune diseases and plaque psoriasis; cardiovascular treatments; and next-generation cell therapies including CAR T-cell therapies. Notable brands and products include Eliquis, Revlimid, and the oral TYK2 inhibitor Sotyktu, which is used for plaque psoriasis. Founded in 1887 and headquartered in Princeton, New Jersey, Bristol Myers Squibb operates globally with a strong presence in the United States, Europe, and other international markets. The company has expanded its oncology and immunology portfolio through a series of significant acquisitions in recent years, including Mirati Therapeutics in January 2024 for $4.8 billion plus milestone payments, Karuna Therapeutics in March 2024 for $14 billion, and the purchase of Turning Point Therapeutics in August 2022 for $4.1 billion. In 2025, Bristol Myers Squibb further diversified its cell therapy portfolio by acquiring Orbital Therapeutics for $1.5 billion, enhancing its pipeline with RNA-based experimental therapies targeting autoimmune disorders. Recent strategic initiatives include launching a direct-to-patient platform offering significant discounts on therapies such as Sotyktu, aiming to improve patient access and affordability. The company also invests in artificial intelligence collaborations to improve drug discovery efficiency and precision in clinical trials. Continued product innovation is expected, with plans to launch 16 new products through 2030, underscoring a growth strategy focused on specialty biopharma segments with high unmet medical needs. Bristol Myers Squibb’s operations are supported by a robust network of partnerships and subsidiaries, solidifying its position in the pharmaceutical industry as a leader in innovative biopharmaceutical solutions. These activities reflect Bristol Myers Squibb's transformation from a diversified pharmaceutical company to a specialty biopharma leader focusing on advanced therapies in oncology, immunology, and cardiovascular diseases, backed by strategic acquisitions, cutting-edge technology partnerships, and patient-centric service offerings.